(Q34424633)

2 August 2017

title

Role of early repeated renal biopsies in lupus nephritis (English)

1 reference

2 August 2017

3

E Svenungsson

1 reference

2 August 2017

A Zickert

1

1 reference

2 August 2017

B Sundelin

series ordinal

2

1 reference

2 August 2017

I Gunnarsson

series ordinal

4

1 reference

2 August 2017

publication date

6 August 2014

1 reference

2 August 2017

published in

Lupus science & medicine

1 reference

2 August 2017

volume

1

1 reference

2 August 2017

issue

1

1 reference

2 August 2017

page(s)

e000018

1 reference

Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis

2 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213828

Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213828

American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213828

Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213828

Therapy of lupus nephritis: lessons learned from clinical research and daily care of patients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213828

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213828

Lupus nephritis: where are we now?

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213828

Biomarkers for lupus nephritis: the quest continues

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213828

European consensus statement on the terminology used in the management of lupus glomerulonephritis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213828

The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213828

Relationship between albuminuria and total proteinuria in systemic lupus erythematosus nephritis: diagnostic and therapeutic implications

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213828

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213828

Antinuclear autoantibodies in systemic lupus erythematosus

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213828

The classification of glomerulonephritis in systemic lupus erythematosus revisited

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213828

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213828

The 1982 revised criteria for the classification of systemic lupus erythematosus

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213828

Prognostic factors in lupus nephritis. Contribution of renal histologic data

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213828

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213828

Frequency of class III and IV nephritis in systemic lupus erythematosus without clinical renal involvement: an analysis of predictive measures.

6 July 2018

1 reference

https://api.crossref.org/works/10.1136%2FLUPUS-2014-000018

Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FLUPUS-2014-000018

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FLUPUS-2014-000018

Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FLUPUS-2014-000018

Strategy for second kidney biopsy in patients with lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FLUPUS-2014-000018

Systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FLUPUS-2014-000018

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FLUPUS-2014-000018

Assessment of a lupus nephritis cohort over a 30-year period.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FLUPUS-2014-000018

Renal biopsy in lupus patients with low levels of proteinuria.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213828

Repeated renal biopsy in proliferative lupus nephritis--predictive role of serum C1q and albuminuria.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213828

Clinical and prognostic value of serial renal biopsies in lupus nephritis

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4213828

Rituximab-treated membranous lupus nephritis: clinical outcome and effects on electron dense deposits

27 October 2018

1 reference

12 December 2020

The pathogenesis and prognosis of lupus nephritis: information from repeat renal biopsy

1 reference

12 December 2020

Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis

1 reference

12 December 2020

Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis

1 reference

12 December 2020

The landscape after LUNAR: rituximab's crater-filled path

1 reference

12 December 2020

The long-term outcome of 93 patients with proliferative lupus nephritis

1 reference

12 December 2020

10.1136/LUPUS-2014-000018

Identifiers

DOI

1 reference

2 August 2017

1 reference

2 August 2017

1 reference